- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00166400
A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.
July 23, 2008 updated by: Mayo Clinic
Beta Blockade in Mitral Regurgitation
Mitral valve regurgitation (leakage of the mitral valve of the heart) is frequent and currently there is no specific medical therapy.
Mitral regurgitation is a slowly progressive disease that frequently requires surgical treatment.
This randomized clinical trial will use Metoprolol, a common beta-blocker medication, to determine if medical treatment impacts mitral valve disease progression.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Background: Mitral regurgitation (MR) is frequent and its prevalence is increasing with aging of the population.
Organic MR, due to primary valvular lesions has severe consequences determined by its degree, with left ventricular (LV) remodeling and dysfunction, left atrial (LA) enlargement, leading to poor clinical outcome.
Surgery can eliminate MR, but carries notable risks and is not applicable to all patients.
Recent animal data suggest that beta-blockade in organic MR has significant positive effect, particularly on LV remodeling.
Therefore, chronically decreasing MR, protecting LV and LA with beta-blockade are major goals of medical therapy.
However, effects of chronic oral beta-blockade of human MR are uncertain and recent practice guidelines underscored these gaps in knowledge and did not recommend beta-blockade of MR.
Hence, a trial of treatment of organic MR is needed.
A large trial with mortality-morbidity end-points is desirable but premature without knowledge of magnitude of mechanistic effects of beta-blockade.
The improvement of these intermediate end-points, mechanistically linked to outcome, is measurable with non-invasive quantitative techniques and forms the basis of the present clinical trial proposal.
Hypothesis: Chronic beta-blockade therapy using Metoprolol weighed against placebo produces a sustained reduction of the consequences of organic MR.
Specific aims are that treatment improves a) degree of MR (decreases regurgitant volume, primary end-point), b) LV remodeling (decreases LV end-diastolic volume index, second end-point), and c) LA enlargement (decreases LA volume, third end-point) as compared to placebo.
Population: Patients with MR organic (intrinsic valve disease), isolated (no other valve disease) d moderate (regurgitant volume *30 mL/beat).
Methods: A randomized clinical trial, placebo controlled, double-blind, without crossover, of 12 months oral treatment with potent beta-blockade (Metoprolol XL 50 to 200mg QD) titrated to the maximally tolerated dose.
The trial is preceded by an acute study to determine tolerance.
End-points are measured by Doppler-Echocardiography for quantitation of MR (regurgitant volume) using combination of 3 simultaneous methods (quantitative Doppler, two-dimensional echocardiography, proximal flow convergence) and echocardiography for LV and LA volume measurement.
In addition cardiopulmonary exercise testing will measure peak O2 consumption at baseline and follow-up.
This study seeks to enroll a total of 60 patients.
The analysis will be based on intention to treat and compare changes in regurgitant volume, LV end-diastolic volume index and LA volume measured after one year of treatment with active drug or placebo.
The results of this clinical trial should provide strong evidence regarding medical treatment of patients with organic MR and define future strategies to minimize mortality and morbidity of organic MR.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria: Patients a) 21 years old or older, with b) MR observed with color flow imaging, c) due to organic mitral valve disease demonstrated by Echocardiography (not normal valve as in functional or ischemic MR), c) isolated (no valve disease other than functional tricuspid regurgitation by Doppler-Echocardiography), d) pure (no mitral stenosis by Doppler-Echocardiography), e) quantifiable by Doppler-Echocardiography, f) of degree * moderate, defined as RVol * 30 mL/beat, g) occurring on native valves, h) with echocardiographic imaging allowing assessment of LA and LV, and i) asymptomatic (or mildly symptomatic but not considered as candidates for immediate surgery by their attending physician).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Degree of mitral regurgitation, assessed as the regurgitant volume, at baseline and 12 months
Time Frame: baseline & 12 months
|
baseline & 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Left ventricular end-diastolic volume index at baseline and 12 months
Time Frame: baseline & 12 months
|
baseline & 12 months
|
Left atrial end-diastolic volume at baseline and at 12 months
Time Frame: baseline & 12 months
|
baseline & 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Maurice E Sarano, M.D., Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Primary Completion (Actual)
July 1, 2007
Study Completion (Actual)
July 1, 2007
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 14, 2005
Study Record Updates
Last Update Posted (Estimate)
July 24, 2008
Last Update Submitted That Met QC Criteria
July 23, 2008
Last Verified
July 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Mitral Valve Insufficiency
- Heart Valve Diseases
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Metoprolol
Other Study ID Numbers
- 960-04
- IRUSMETO0047, IRB 960-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Valve Diseases
-
National Heart, Lung, and Blood Institute (NHLBI)WithdrawnHeart Failure | Aortic Valve Stenosis | Mitral Valve Regurgitation | Heart Valve Disease | Tricuspid Valve RegurgitationUnited States
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
-
Caisson Interventional LLCActive, not recruitingMitral Regurgitation | Valve Disease, Heart | Valve Heart Disease | Mitral Valve Disease | Mitral Valve Failure | Mitral DiseaseUnited States
-
UMC UtrechtLeiden University Medical Center; The Interuniversity Cardiology Institute... and other collaboratorsTerminatedMitral Valve Insufficiency | Diseases of Mitral Valve | Heart; Disease, Mitral(Valve)Netherlands
-
Edwards LifesciencesRecruitingCardiovascular Diseases | Heart Failure | Heart Valve Diseases | Tricuspid Valve Regurgitation | Tricuspid Valve Insufficiency | Tricuspid Valve DiseaseUnited States, Germany
-
Synecor, LLCUnknownHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Disease
-
Edwards LifesciencesActive, not recruitingHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve DiseaseUnited States, Australia, Brazil
-
Universitätsklinikum Hamburg-EppendorfRecruitingAortic Valve Disease | Heart Valve Diseases | Mitral Valve Disease | Tricuspid Valve DiseaseGermany
-
Astana Medical UniversityCompletedMitral Valve Insufficiency | Aortic Valve InsufficiencyKazakhstan
Clinical Trials on metoprolol succinate
-
SanionaCompleted
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
University of MinnesotaUniversity of Alabama at Birmingham; United States Department of DefenseTerminatedPulmonary Disease, Chronic ObstructiveUnited States
-
University of CincinnatiTerminated
-
Gilead SciencesAstraZenecaTerminatedEnoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart FailureHeart Failure, CongestiveUnited States
-
CytokineticsRecruitingObstructive Hypertrophic Cardiomyopathy (oHCM)United States, Denmark, Spain, Netherlands, United Kingdom, France, China, Israel, Germany, Italy, Hungary, Canada
-
Damanhour Teaching HospitalRecruitingHypotension Drug-InducedEgypt
-
University of MichiganCompletedHemodialysis | PharmacokineticsUnited States
-
AstraZenecaCompletedHypertensionUnited States, Dominican Republic
-
Hackensack Meridian HealthTerminatedCOVID-19 | Tachycardia | DyspneaUnited States